A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

NCT ID: NCT00952445


Title
A Randomized, Double-Blind, Placebo-Controlled, 4-week Study to Evaluate the Safety and Efficacy of T0903131 Besylate in Subjects With Type 2 Diabetes Mellitus
Purpose
The purpose of the study is to determine if repeated daily doses of T0903131 (INT131) Besylate over 4 weeks can lower fasting blood glucose in patients with Type 2 Diabetes Mellitus.
Details
Conditions
Diabetes Mellitus, Type II
Keywords
Source
InteKrin Therapeutics, Inc.
Sponsors
InteKrin Therapeutics, Inc.
Status
Completed
Acronym
Last Updated
04 Aug 2009
URL
Official Link
Locations
United States